FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366751239> ?p ?o ?g. }

• W4366751239 endingPage "957" @default.
• W4366751239 startingPage "947" @default.
• W4366751239 abstract "To compare the efficacy and the safety of submacular hemorrhage (SMH) management using either surgical pars plana vitrectomy (PPV) or pneumatic displacement (PD) with tissue plasminogen activator (tPA) and vascular endothelial growth factor (VEGF) inhibitor added to each arm.Randomized, open-label, multicenter superiority study.Ninety patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older with recent SMH (≤ 14 days) of more than 2 optic disc areas and predominantly overlying the retinal pigment epithelium.Patients were assigned randomly to surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride [SF6] tamponade) or PD (0.05 ml intravitreal tPA [50 μg] and 0.3 ml intravitreal pure SF6). Both groups were asked to maintain a head upright position with the face forward at 45° for 3 days after intervention and received 0.5 mg intravitreal ranibizumab at the end of the intervention, at months 1 and 2, as the loading phase, and then on a pro re nata regimen during a 6-month follow-up.The primary efficacy endpoint was mean best-corrected visual acuity (VA) change at month 3. The secondary endpoints were mean VA change at month 6, 25-item National Eye Institute Visual Function Questionnaire composite score value at months 3 and 6, number of anti-VEGF injections, and complications during the 6-month follow-up.Of the 90 patients randomized, 78 patients (86.7%) completed the 3-month efficacy endpoint visit. The mean VA change from baseline to month 3 in the surgery group (+16.8 letters [95% confidence interval (CI), 8.7-24.9 letters]) was not significantly superior to that in the PD group (+16.4 letters [95% CI, 7.1-25.7 letters]; adjusted difference β, 1.9 [-11.0; 14.9]; P = 0.767). Both groups achieved similar secondary outcomes at month 6. No unexpected ocular safety concerns were observed in either group.Surgery did not yield superior visual gain nor additional benefit for SMH secondary to nAMD compared with PD at 3 months, with intravitreal anti-VEGF added to each arm. Both treatment strategies lead to a clinical improvement of VA without safety concerns for SMH over 6 months. Both design and results of the trial cannot be used to establish equivalence between treatments.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article." @default.
• W4366751239 created "2023-04-24" @default.
• W4366751239 creator A5031143082 @default.
• W4366751239 creator A5032675544 @default.
• W4366751239 creator A5043645169 @default.
• W4366751239 creator A5058529710 @default.
• W4366751239 creator A5061223187 @default.
• W4366751239 creator A5061783443 @default.
• W4366751239 creator A5061933063 @default.
• W4366751239 creator A5062605294 @default.
• W4366751239 creator A5083564913 @default.
• W4366751239 creator A5091241709 @default.
• W4366751239 date "2023-09-01" @default.
• W4366751239 modified "2023-10-15" @default.
• W4366751239 title "Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study" @default.
• W4366751239 cites W1259602996 @default.
• W4366751239 cites W142950300 @default.
• W4366751239 cites W1551250108 @default.
• W4366751239 cites W1979435410 @default.
• W4366751239 cites W1981910175 @default.
• W4366751239 cites W1988488084 @default.
• W4366751239 cites W1999932917 @default.
• W4366751239 cites W2028465838 @default.
• W4366751239 cites W2043885997 @default.
• W4366751239 cites W2054688806 @default.
• W4366751239 cites W2057533513 @default.
• W4366751239 cites W2090073750 @default.
• W4366751239 cites W2090793379 @default.
• W4366751239 cites W2096060458 @default.
• W4366751239 cites W2125587232 @default.
• W4366751239 cites W2323046822 @default.
• W4366751239 cites W2333161755 @default.
• W4366751239 cites W2593807616 @default.
• W4366751239 cites W2899340650 @default.
• W4366751239 cites W3039500772 @default.
• W4366751239 cites W3132797619 @default.
• W4366751239 cites W318413158 @default.
• W4366751239 cites W3197144651 @default.
• W4366751239 cites W4210618857 @default.
• W4366751239 cites W4220891892 @default.
• W4366751239 cites W4233230329 @default.
• W4366751239 cites W4288061036 @default.
• W4366751239 doi "https://doi.org/10.1016/j.ophtha.2023.04.014" @default.
• W4366751239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37088447" @default.
• W4366751239 hasPublicationYear "2023" @default.
• W4366751239 type Work @default.
• W4366751239 citedByCount "1" @default.
• W4366751239 countsByYear W43667512392023 @default.
• W4366751239 crossrefType "journal-article" @default.
• W4366751239 hasAuthorship W4366751239A5031143082 @default.
• W4366751239 hasAuthorship W4366751239A5032675544 @default.
• W4366751239 hasAuthorship W4366751239A5043645169 @default.
• W4366751239 hasAuthorship W4366751239A5058529710 @default.
• W4366751239 hasAuthorship W4366751239A5061223187 @default.
• W4366751239 hasAuthorship W4366751239A5061783443 @default.
• W4366751239 hasAuthorship W4366751239A5061933063 @default.
• W4366751239 hasAuthorship W4366751239A5062605294 @default.
• W4366751239 hasAuthorship W4366751239A5083564913 @default.
• W4366751239 hasAuthorship W4366751239A5091241709 @default.
• W4366751239 hasBestOaLocation W43667512391 @default.
• W4366751239 hasConcept C118487528 @default.
• W4366751239 hasConcept C126322002 @default.
• W4366751239 hasConcept C141071460 @default.
• W4366751239 hasConcept C168563851 @default.
• W4366751239 hasConcept C203092338 @default.
• W4366751239 hasConcept C2776403814 @default.
• W4366751239 hasConcept C2776572282 @default.
• W4366751239 hasConcept C2776694085 @default.
• W4366751239 hasConcept C2777063560 @default.
• W4366751239 hasConcept C2777573719 @default.
• W4366751239 hasConcept C2777802072 @default.
• W4366751239 hasConcept C2778257484 @default.
• W4366751239 hasConcept C2780699112 @default.
• W4366751239 hasConcept C2781100027 @default.
• W4366751239 hasConcept C2781242345 @default.
• W4366751239 hasConcept C2781359195 @default.
• W4366751239 hasConcept C71924100 @default.
• W4366751239 hasConceptScore W4366751239C118487528 @default.
• W4366751239 hasConceptScore W4366751239C126322002 @default.
• W4366751239 hasConceptScore W4366751239C141071460 @default.
• W4366751239 hasConceptScore W4366751239C168563851 @default.
• W4366751239 hasConceptScore W4366751239C203092338 @default.
• W4366751239 hasConceptScore W4366751239C2776403814 @default.
• W4366751239 hasConceptScore W4366751239C2776572282 @default.
• W4366751239 hasConceptScore W4366751239C2776694085 @default.
• W4366751239 hasConceptScore W4366751239C2777063560 @default.
• W4366751239 hasConceptScore W4366751239C2777573719 @default.
• W4366751239 hasConceptScore W4366751239C2777802072 @default.
• W4366751239 hasConceptScore W4366751239C2778257484 @default.
• W4366751239 hasConceptScore W4366751239C2780699112 @default.
• W4366751239 hasConceptScore W4366751239C2781100027 @default.
• W4366751239 hasConceptScore W4366751239C2781242345 @default.
• W4366751239 hasConceptScore W4366751239C2781359195 @default.
• W4366751239 hasConceptScore W4366751239C71924100 @default.
• W4366751239 hasIssue "9" @default.
• W4366751239 hasLocation W43667512391 @default.
• W4366751239 hasLocation W43667512392 @default.
• W4366751239 hasLocation W43667512393 @default.

• next